MAP3K7CL Antikörper (C-Term)
Kurzübersicht für MAP3K7CL Antikörper (C-Term) (ABIN629829)
Target
Alle MAP3K7CL Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- C-Term
-
Spezifität
- C21 ORF7 antibody was raised against the C terminal Of C21 rf7
-
Aufreinigung
- Purified
-
Immunogen
- C21 ORF7 antibody was raised using the C terminal Of C21 rf7 corresponding to a region with amino acids DSEESMEVFKQHCQIAEEYHEVKKEITLLEQRKKELIAKLDQAEKEKVDA
-
-
-
-
Applikationshinweise
-
WB: 1.25 µg/mL, IHC: 4-8 µg/mL
Optimal conditions should be determined by the investigator. -
Kommentare
-
C21ORF7 Blocking Peptide, (ABIN937547), is also available for use as a blocking control in assays to test for specificity of this C21ORF7 antibody
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Rekonstitution
- Lyophilized powder. Add distilled water for a 1 mg/mL concentration of C20 RF7 antibody in PBS
-
Konzentration
- Lot specific
-
Buffer
- PBS
-
Handhabung
-
Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use. -
Lagerung
- 4 °C/-20 °C
-
Informationen zur Lagerung
- Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.
-
-
- MAP3K7CL (MAP3K7 C-Terminal Like (MAP3K7CL))
-
Andere Bezeichnung
- C21ORF7
-
Hintergrund
- C21orf7 plays a critical role in the TGF-beta signaling transduction pathway.
-
Molekulargewicht
- 27 kDa (MW of target protein)
Target
-